Mace(R) Security International, a Global Leader in Personal Self-Defense Sprays, Announces Preliminary 3Q24 Financial Results and Notification of Late Filing
CLEVELAND, OH / ACCESSWIRE / November 14, 2024 / Mace Security International (OTCQB:MACE) today announced its September 30, 2024 Unaudited Financial Statements and Notes and 2024 Q3 OTCQB Quarterly Report cannot be filed within the prescribed date because the Company requires additional time to prepare its financial statements and quarterly reports. The Company anticipates filing these two reports before the end of the cure period under the OTCQB Standards on December 30, 2024.
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. Veterinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dysfunction (PPID), with prevalence reported between 18-27% of ponies and horses.
KindlyMD(R) Announces Third Quarter 2024 Financial Results
Q3 Reimbursements from insurance payors totaled $106,567 an increase of 16.4% sequentially KindlyMD now provides more than 90% in-network insurance coverage in Utah SALT LAKE CITY, UT / ACCESSWIRE / November 13, 2024 / ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company redefining value-based care and patient-centered medical services, today announced its financial results for the third quarter ended September 30, 2024. "We are pleased with the progress made during the third quarter to expand our credentialing and increase insurance visits, resulting in a 16.4% growth sequentially.
Theralase(R) Extends Warrants
TORONTO, ON / ACCESSWIRE / November 12, 2024 / Theralase® Technologies Inc. ("Theralase ®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,000,000 share purchase warrants ("Warrants") from November 17, 2024 to November 17, 2027. The Warrants were issued on November 17, 2022, pursuant to a private placement involving the issuance of 1,000,000 units of the Company.
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based hydrogel, including improved biocompatibility and extended shelf life. Per this new clearance, Sonoma's Microdacyn® Hydrogel can be used under the supervision of a healthcare professional for management of wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, for use on first and second degree burns, and diabetic ulcers, and for the management of mechanically or surgically debrided wounds.
Atlantic Power & Infrastructure Corp. (AP&I)'s Proprietary Product, Flexi(R)-Pave, Proves Once Again to Be the Ideal Solution for Urban Landscaping and Maintenance
TAMPA BAY, FL / ACCESSWIRE / November 6, 2024 / Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) is pleased to announce that its proprietary product, Flexi®-Pave, has proved once again to be a major success for tree surround installations in the City of Las Vegas, Nevada, leading to the approval of more planned projects for city maintenance and beautification in the coming year. The product's unique composition allows for flexibility, aeration and filtration while mitigating the liability so often associated with broken concrete and asphalt and tree root hazards.
NXT Energy Solutions Announces The Award Of An SFD(R) Survey Contract
CALGARY, AB / ACCESSWIRE / November 5, 2024 / NXT Energy Solutions Inc. ("NXT" or the "Company") (TSX:SFD)(OTCQB:NSFDF) is pleased to announce the award of a contract to provide an SFD® survey for AL-Haj Enterprises Private Limited ("AEPL"). Data acquisition operations for this contract are expected to commence in the second quarter of 2025, and NXT's interpretations and recommendations are expected to be delivered during the third quarter of 2025.
KindlyMD(R) Announces New Partnership With Cigna Healthcare to Further Expand Patient Care Accessibility
KindlyMD now provides more than 90% statewide comprehensive insurance coverage SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced it is now contracted with Cigna Healthcare, after receiving additional credentialing. Cigna's innovative approach to behavioral health focuses on integrating mental health services with primary care and ensuring that individuals receive comprehensive support tailored to their unique needs.
Ryder Stock Barely Moves Higher Since Q3 Earnings Release
R now expects its 2024 adjusted earnings guidance between $11.90 and $12.10 per share compared with the prior guided view of $11.90-$12.40.
Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements
LOS GATOS, CA / ACCESSWIRE / October 28, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that it is in compliance with all relevant Nasdaq continued listing Rules. The Company had previously reported non compliance with Nasdaq Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2), with respect to the number of independent directors on its board of directors and certain board committees; Nasdaq Rule 5550(a)(2), with respect to its minimum bid price; Nasdaq Rule 5550(a)(4), with respect to number of shares in its public float; and Nasdaq Rule 5550(b), with respect to its stockholders' equity.
Mace(R) Security International, a Global Leader in Personal Self-Defense Sprays, Announces Postponement of Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / October 28, 2024 / Mace Security International (OTCQB:MACE) today announced that, due the recently announced Agreement and Plan of Merger, the previously announced 2024 Annual Meeting of Shareholders is postponed and will be rescheduled if and as necessary pending the potential merger transaction contemplated by the Agreement and Plan of Merger. Separately, a Special Meeting of Shareholders will be called to vote on the Agreement and Plan of Merger.
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology® 2024 Annual Scientific Meeting taking place October 25-30 in Philadelphia, PA. This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality.
